Jaguar Land Rover Cyber Attack Creates £1.9 Billion Ripple Effect Across UK Supply Chain
Manufacturing Giant’s Security Breach Sends Shockwaves Through British Economy The recent cyber attack targeting Jaguar Land Rover has unleashed a…
Manufacturing Giant’s Security Breach Sends Shockwaves Through British Economy The recent cyber attack targeting Jaguar Land Rover has unleashed a…
Xbox Development Tools Join Growing List of Microsoft Price Increases Microsoft is extending its recent wave of price adjustments beyond…
Next-Generation Maritime Drones Transform Naval Combat Ukraine’s Security Service has revealed significant advancements in its naval drone capabilities, with the…
OpenBSD 7.8 Delivers Enhanced Platform Compatibility The latest release of OpenBSD brings significant improvements to hardware support and security features.…
Breakthrough in Biomimetic Droplet Research Scientists have developed a remarkable system of self-regulating droplets that form, evolve, and dissolve through…
A groundbreaking study demonstrates extended cardiac function improvement using platelet-derived growth factor-AB following myocardial infarction. The research, conducted in a clinically relevant porcine model, shows therapeutic benefits lasting 60 days post-treatment with comprehensive multi-modality assessment.
Researchers have demonstrated extended improvement in cardiac function using platelet-derived growth factor-AB (PDGF-AB) as a therapeutic agent for heart repair following myocardial infarction, according to a recent study published in npj Regenerative Medicine. The preclinical investigation, conducted in a porcine model that closely mimics human heart conditions, reportedly shows promising results for lasting cardiac recovery.
Revolutionizing Single-Cell Analysis with Sequence-Based Modeling In a significant breakthrough for computational biology, researchers have developed scooby, a novel AI…
A comprehensive study examining fenofibrate’s effects reveals striking differences in how liver and kidney tissues respond to the medication. Researchers found significantly stronger metabolic activation in liver tissue compared to kidneys, with implications for understanding drug mechanisms and potential side effects.
New research published in Scientific Reports reveals that fenofibrate, a commonly prescribed lipid-lowering medication, activates metabolic pathways differently in liver and kidney tissues, according to the study findings. The five-day rat exposure study demonstrated that while both organs showed responses to the drug, the liver exhibited significantly stronger activation of lipid metabolism pathways than the kidney.